---
title: "Hormone Replacement Therapy: A Complete Evidence-Based Guide for Menopausal Women"
topic: "Hormone Replacement Therapy Risks and Benefits"
date_created: "2025-12-23"
status: "draft"
word_count: 4200
images: 0
visualizations_needed: 7
sources: "open-agents/output-drafts/hrt-menopause-risks-benefits-research.md"
---

# Hormone Replacement Therapy: A Complete Evidence-Based Guide for Menopausal Women

Two decades after the Women's Health Initiative (WHI) study sent shockwaves through the medical community and caused millions of women to abandon hormone therapy, the scientific consensus has dramatically shifted. In November 2025, the FDA removed the black box warnings from many hormone replacement products, acknowledging that the original findings presented a misleadingly alarming picture.[^1] What we now understand is far more nuanced: the risks and benefits of hormone replacement therapy (HRT) depend critically on when it's started, how it's delivered, and who's taking it.

For the estimated 1.3 million women who enter menopause each year in the United States alone, this evolving understanding represents a crucial opportunity. Menopausal symptoms—including hot flashes that can persist for 7 to 11 years on average[^2]—significantly impact quality of life, productivity, and long-term health. HRT remains the most effective treatment for these symptoms, yet fear and confusion continue to prevent many women from accessing relief. This comprehensive guide examines the current scientific evidence to help women and their healthcare providers make informed decisions.

## Understanding Menopause and Hormone Therapy

### The Menopausal Transition

Menopause marks the permanent cessation of menstruation, typically occurring around age 51. However, the transition begins earlier during perimenopause, when hormone levels begin fluctuating. This transition brings a constellation of symptoms: vasomotor symptoms (hot flashes and night sweats), sleep disturbances, mood changes, vaginal dryness, and accelerated bone loss. Approximately 27% to 84% of postmenopausal women experience genitourinary syndrome of menopause (GSM), which can significantly impair sexual function and quality of life.[^3]

Hormone replacement therapy works by supplementing the declining estrogen (and sometimes progesterone) levels that underlie these symptoms. The approach has been used since the 1940s, though our understanding of optimal protocols has evolved considerably.

### Types of Hormone Therapy

**Estrogen-Only Therapy (ET)** is prescribed for women who have had a hysterectomy. Without a uterus, there's no risk of endometrial cancer from unopposed estrogen, making progestogen unnecessary. Importantly, the WHI found that estrogen-only therapy reduces breast cancer risk by 23% and breast cancer mortality by 40%—a stark contrast to the increased risk seen with combined therapy.[^4]

**Combined Estrogen-Progestogen Therapy (EPT)** is necessary for women with an intact uterus. Estrogen alone increases endometrial cancer risk; adding a progestogen provides crucial protection. However, this combination carries different risks, including a modest increase in breast cancer risk.

**Bioidentical vs. Synthetic Hormones** remains an area of ongoing debate. Bioidentical hormones (17β-estradiol, progesterone) are chemically identical to those produced by the body. Some evidence suggests natural progesterone may carry lower breast cancer risk than synthetic progestins like medroxyprogesterone acetate (MPA).[^5] However, the FDA and Endocrine Society emphasize that compounded bioidentical hormones lack rigorous testing and quality control, and major medical organizations caution against their use.[^6]

## The Women's Health Initiative: What We Know Now

### The Original Findings

The WHI enrolled 27,347 postmenopausal women between 1993 and 1998 in two parallel hormone therapy trials. The estrogen-plus-progestin arm was halted in 2002 after findings suggested increased risks of coronary heart disease, stroke, blood clots, and breast cancer. Headlines around the world declared hormone therapy dangerous, and prescriptions plummeted by 80% in subsequent years.[^7]

<!-- VIZ: grouped-bar-chart - WHI Outcomes: Estrogen-Only vs Combined Therapy
DATA:
- Breast Cancer: ET HR 0.79, EPT HR 1.24
- Coronary Heart Disease: ET HR 0.94, EPT HR 1.18
- Stroke: ET HR 1.35, EPT HR 1.37
- Venous Thromboembolism: ET HR 1.35, EPT HR 2.0
- Hip Fracture: ET HR 0.67, EPT HR 0.67
- All-Cause Mortality: ET HR 0.99, EPT HR 0.99
SOURCE: https://pmc.ncbi.nlm.nih.gov/articles/PMC3963523/
-->

### The Critical Context Missing from Headlines

What was often lost in the panic was crucial context. The average age of WHI participants was 63—more than a decade past the typical age of menopause. Only 3.5% were aged 50-54, the window when most women consider starting hormone therapy.[^7] Furthermore, many initial findings were not statistically significant when properly adjusted. A critical review noted that after adjustment for multiple comparisons, the breast cancer hazard ratio's confidence interval widened to 0.83-1.92, crossing the null value and indicating no significant effect.[^8]

Even accepting the WHI estimates at face value, the absolute risk was modest: combined therapy was associated with approximately one additional nonfatal breast cancer case per 1,000 women treated annually.[^8] Meanwhile, beneficial effects were often underemphasized: both therapy types reduced hip fracture risk by 33% and provided significant diabetes risk reduction.[^7]

## The Timing Hypothesis: When You Start Matters Profoundly

Perhaps the most important insight from post-WHI research is the "timing hypothesis"—the understanding that HRT's effects depend critically on when therapy begins relative to menopause onset.

### Evidence for Early Initiation Benefits

A comprehensive meta-analysis of randomized controlled trials demonstrated that women who initiate hormone therapy within 10 years of menopause experience significantly different outcomes than those who start later:[^9]

<!-- VIZ: line-chart - Coronary Heart Disease Risk by Years Since Menopause at HRT Initiation
DATA:
- Less than 10 years: HR 0.76 (protective)
- 10-19 years: HR 1.10 (neutral to harmful)
- 20+ years: HR 1.28 (harmful)
SOURCE: https://pmc.ncbi.nlm.nih.gov/articles/PMC9178928/
-->

The ELITE trial, specifically designed to test this hypothesis, confirmed that estradiol treatment slowed progression of carotid artery thickening (a marker of atherosclerosis) when initiated within 6 years of menopause, but provided no benefit when started 10 or more years after menopause. The interaction by age group was statistically significant.[^10]

Recent data presented at The Menopause Society's 2025 Annual Meeting strengthened this finding: perimenopausal women who used estrogen within 10 years prior to menopause showed no significantly higher rates of breast cancer, heart attack, or stroke compared to other groups.[^11]

### Biological Mechanism

The biological explanation appears straightforward: estrogen has beneficial effects on healthy arteries but potentially harmful effects on arteries already affected by atherosclerosis. Animal studies have consistently shown that estrogen prevents atherosclerosis only when initiated at the time of menopause, not later.[^12] This has profound clinical implications—HRT is most beneficial precisely when healthy, younger women might consider it, not when older women with established cardiovascular disease present.

### Age-Stratified Outcomes

The WHI's own age-stratified analysis illustrates this dramatically:[^7]

<!-- VIZ: diverging-bar-chart - Adverse Events per 10,000 Person-Years by Age (CEE Alone)
DATA:
- Ages 50-59: 19 fewer adverse events
- Ages 60-69: Approximately neutral
- Ages 70-79: 51 more adverse events
SOURCE: https://pmc.ncbi.nlm.nih.gov/articles/PMC3963523/
-->

Among women aged 50-59 taking estrogen alone, there were 19 *fewer* adverse events per 10,000 person-years compared to placebo. For women aged 70-79, there were 51 *more* adverse events. This reversal underscores why applying findings from older women to younger ones was scientifically inappropriate.

## Benefits of Hormone Therapy

### Vasomotor Symptom Relief

HRT remains unequivocally the most effective treatment for hot flashes and night sweats. In the WHI, women aged 50-54 with moderate to severe symptoms experienced a 64% reduction in vasomotor symptoms at one year.[^7] No other therapy approaches this level of efficacy. The non-hormonal alternative venlafaxine, by comparison, achieves only a 48% reduction versus 53% for estradiol.[^13]

Given that approximately 40% of women in their 60s and 10-15% in their 70s continue to experience hot flashes,[^2] the need for effective treatment often extends well beyond the menopausal transition.

### Bone Health and Fracture Prevention

Hormone therapy is the only anti-osteoporotic treatment proven effective regardless of baseline fracture risk.[^14] The benefits are substantial:

<!-- VIZ: horizontal-bar-chart - HRT Benefits: Risk Reduction Percentages
DATA:
- Vasomotor symptoms at 1 year: 64% reduction
- Hip fracture: 34% reduction
- All fractures: 24% reduction
- Dementia (early initiation): 32% reduction
- Cardiovascular disease (early initiation): up to 50% reduction
- Diabetes: 14-19% reduction
SOURCES: Multiple meta-analyses and WHI data
-->

The WHI demonstrated a 34% reduction in hip fracture and 24% reduction in all fractures, benefits that persisted regardless of baseline bone mineral density.[^15] For women at high osteoporosis risk—particularly those with premature menopause (before age 40) or early menopause (before age 45)—HRT provides crucial protection during the years of accelerated bone loss.

### Cognitive Effects

The relationship between HRT and cognitive function depends critically on timing. Mid-life estrogen therapy is associated with a 32% lower rate of dementia, while late-life initiation shows no benefit and may even cause harm.[^16] A 2024 meta-analysis of 34 randomized controlled trials found that estrogen therapy for surgical menopause improved global cognition, and when initiated specifically at midlife, improved verbal memory.[^17]

This pattern aligns with the timing hypothesis: estrogen appears neuroprotective when administered to healthy brains but potentially harmful when brain pathology is already established. APOE-ε4 carriers—women at increased genetic risk for Alzheimer's disease—may not benefit from HRT and could potentially experience harm with late or prolonged use.[^18]

### Cardiovascular Protection (Early Initiation)

When initiated within 10 years of menopause or before age 60, HRT is associated with:[^9]

- Reduced coronary heart disease risk (HR 0.76)
- Potential reduction in cardiovascular disease by up to 50%[^1]
- Significant reduction in all-cause mortality

Meta-analyses of cumulative randomized controlled trial data show that HRT significantly reduces all-cause mortality and cardiovascular disease when initiated in women under 60 years of age—effects that other primary prevention therapies like statins have not demonstrated in this population.[^9]

### Quality of Life and Sexual Function

Beyond specific disease outcomes, HRT improves overall quality of life. A meta-analysis of 24 studies found significant improvement in menopause-specific quality of life scores, improved vaginal health, and elevated estrogen levels.[^19] For the up to 84% of postmenopausal women affected by genitourinary syndrome of menopause, hormone therapy is first-line treatment for symptoms that negatively affect enjoyment of sexual activity (59% of affected women), sleep (24%), and overall enjoyment of life (23%).[^3]

## Risks of Hormone Therapy

### Breast Cancer

The breast cancer risk from HRT is perhaps the most anxiety-provoking concern, yet the evidence is more nuanced than commonly understood:

**Combined Therapy (EPT):** The WHI found an increased risk (HR 1.24) that persists through two decades of follow-up. However, the absolute risk is approximately one additional case per 1,000 women per year.[^7][^8] Risk increases with duration of use. The type of progestogen matters: synthetic progestins like MPA appear to carry higher risk than natural progesterone.[^20]

**Estrogen-Only Therapy:** In direct contrast, estrogen alone *decreases* breast cancer incidence (HR 0.79) and breast cancer mortality by 40%.[^4] This finding, confirmed over 20 years of follow-up, is often underemphasized.

<!-- VIZ: comparative-bar-chart - Breast Cancer Risk by HRT Type
DATA:
- No HRT: Baseline (1.0)
- Estrogen-Only: 23% lower risk (HR 0.77)
- Combined with natural progesterone: Slightly elevated risk
- Combined with synthetic progestins: 24% higher risk (HR 1.24)
SOURCES: https://pmc.ncbi.nlm.nih.gov/articles/PMC3963523/ and https://pmc.ncbi.nlm.nih.gov/articles/PMC1974841/
-->

### Venous Thromboembolism

Blood clot risk is genuinely elevated with oral HRT, with meta-analyses showing a relative risk of 1.86 (95% CI 1.39-2.50)—nearly double the baseline risk.[^21] The risk is highest in the first year, with some studies reporting up to 6-fold increases in the first months of use.[^22]

However, route of administration is critically important:

<!-- VIZ: comparison-bar-chart - VTE Risk by Route of Administration
DATA:
- Oral HRT: RR 1.9 (95% CI 1.3-2.3)
- Transdermal HRT: RR 1.0 (95% CI 0.9-1.1) - no increased risk
SOURCE: https://pmc.ncbi.nlm.nih.gov/articles/PMC9399360/
-->

Transdermal estrogen shows no significant increase in VTE risk because it bypasses first-pass liver metabolism, which increases clotting factors.[^22] For women with VTE risk factors—obesity, older age, thrombophilia, smoking—transdermal delivery is strongly preferred.

### Stroke

Meta-analyses consistently show HRT increases stroke risk by approximately 23-32%.[^21][^23] This risk appears limited to ischemic (not hemorrhagic) stroke and is present during but not after HRT use.[^23] Transdermal administration and vaginal estrogen do not appear to increase stroke risk, while oral therapy does.[^24]

### Other Risks

- **Gallbladder disease:** Both HRT types increase risk by approximately 50%, an effect that persists after stopping.[^7] Transdermal formulations carry lower risk.
- **Urinary incontinence:** Paradoxically, systemic HRT may worsen incontinence (HR 1.49-1.61).[^7]
- **Ovarian cancer:** A modest increased risk exists, particularly with estrogen-only therapy, though progestogen appears to mitigate this.[^25]

## Route of Administration: Transdermal vs. Oral

The route by which hormones are delivered significantly affects their safety profile.

### Transdermal Advantages

Patches, gels, and sprays bypass first-pass liver metabolism, leading to:[^26]

- **No increased VTE risk** (RR 1.0 vs. 1.9 for oral)
- **Lower doses required** (10-20 times lower than oral for equivalent effects)
- **More favorable triglyceride effects**
- **Reduced gallbladder disease risk**
- **Lower anxiety and depression incidence**

A 2023 systematic review concluded that the overall risk-benefit profile of transdermal HRT makes it a more attractive option than oral therapy.[^26]

### Who Should Use Transdermal

Transdermal delivery is particularly recommended for:[^22][^26]

- Women with VTE risk factors (prior clots, Factor V Leiden, family history)
- Obese women (oral HRT causes 3-fold VTE increase in overweight women)
- Women over 60
- Smokers
- Those with migraine with aura
- Women with hypertriglyceridemia

### Vaginal Estrogen

Low-dose vaginal estrogen is specifically indicated for genitourinary syndrome of menopause and provides relief for vulvovaginal atrophy and dyspareunia with minimal systemic absorption. The 2025 AUA/SUFU/AUGS guidelines recommend it as first-line therapy for GSM.[^27] It does not significantly increase VTE or stroke risk and may actually be associated with *reduced* stroke risk.[^24]

## Duration of Therapy: How Long Is Safe?

### Current Guidelines

Medical guidelines have evolved significantly on duration:

- **ACOG and The Menopause Society:** No maximum duration for MHT use[^2]
- **NHS:** No definitive limit on HRT duration[^28]
- **Previous 5-year limits:** Not based on quality evidence[^29]

The key principle is individualization. A 2017 JAMA study found that taking HRT for 5-7 years was not associated with long-term mortality risks.[^30] Long-term data show no evidence of harm with appropriate use when prescribed to suitable candidates.

### Practical Considerations

- Symptoms often last longer than previously thought (average 7-11 years for vasomotor symptoms)
- Annual review with healthcare provider is recommended
- Lower doses may be sufficient for older women
- Transdermal route preferred for longer-term use
- The Menopause Society confirms women up to age 80 can benefit from individualized therapy[^31]

## Individual Risk Factors: Who Benefits Most?

### Ideal Candidates

The best candidates for HRT are:[^9][^32]

- Women under 60 or within 10 years of menopause
- Those with moderate to severe vasomotor symptoms
- Women without contraindications (see below)
- Those at elevated osteoporosis risk
- Women with premature or early menopause (particularly important)
- Surgically menopausal women (oophorectomy)

### Contraindications (Avoid HRT)

Hormone therapy is contraindicated in women with:[^32][^33]

- History of breast cancer
- Active venous thromboembolism or pulmonary embolism
- History of stroke or myocardial infarction
- Active liver disease
- Undiagnosed vaginal bleeding
- Coronary artery dissection (never oral estrogen)

### High-Risk Situations (Careful Evaluation Required)

Women with the following conditions require individualized risk assessment:[^32]

- Atherosclerotic cardiovascular disease
- 10-year ASCVD risk ≥10%
- Family history of breast cancer
- Thrombophilia (Factor V Leiden dramatically amplifies VTE risk)
- Multiple cardiovascular risk factors

### Risk Mitigation Strategies

For women who need HRT but have elevated risk:[^22][^26]

- Use transdermal rather than oral estrogen
- Choose bioidentical progesterone over synthetic progestins when possible
- Use lowest effective dose
- Consider vaginal estrogen for localized symptoms only
- Regular monitoring and annual review

## Making the Decision: A Framework

### Step 1: Assess Symptom Burden

Consider whether menopausal symptoms are significantly impacting quality of life, sleep, work productivity, or relationships. Remember that vasomotor symptoms can persist for over a decade and that genitourinary symptoms often worsen without treatment.

### Step 2: Evaluate Personal Risk Profile

Consider:
- Age and time since menopause (favorable if <60 or <10 years since menopause)
- Personal and family history of breast cancer, VTE, stroke, cardiovascular disease
- Presence of obesity, smoking, or other risk factors
- Bone health and osteoporosis risk

### Step 3: Consider Therapy Options

Based on risk assessment:
- **Intact uterus:** Combined EPT required; consider micronized progesterone over synthetic progestins
- **Post-hysterectomy:** Estrogen-alone therapy (more favorable risk profile)
- **Elevated VTE/stroke risk:** Transdermal delivery
- **GSM only:** Low-dose vaginal estrogen

### Step 4: Ongoing Monitoring

- Annual review with healthcare provider
- Reassess symptom burden and risk factors periodically
- Adjust dose, route, or formulation as needed
- No predetermined stopping point—base decisions on individual circumstances

## Key Takeaways

- **Timing is crucial:** HRT initiated before age 60 or within 10 years of menopause has a favorable risk-benefit profile; later initiation may pose risks without benefits
- **Not all HRT is equal:** Estrogen-only therapy (for hysterectomized women) reduces breast cancer risk; combined therapy modestly increases it
- **Route matters:** Transdermal delivery avoids the blood clot and stroke risks associated with oral therapy
- **Duration is individualized:** No maximum treatment length; decisions should be based on ongoing symptom burden and risk assessment
- **The evidence has evolved:** The 2002 WHI findings, applied to a predominantly older population, should not prevent younger symptomatic women from accessing effective treatment

## Conclusion

The landscape of hormone replacement therapy has transformed since the alarm bells of 2002. We now understand that for the right woman at the right time, HRT offers significant benefits—relief from debilitating symptoms, protection against bone loss, and potentially reduced cardiovascular and cognitive risks—with manageable risks. The 2025 removal of FDA black box warnings reflects this evolved understanding.

For women experiencing menopausal symptoms, the decision about HRT is deeply personal and should be made in partnership with a knowledgeable healthcare provider. The goal is not to convince everyone to take hormones, nor to frighten women away from effective treatment. It is to ensure that every woman has access to accurate, evidence-based information to make the choice that's right for her individual circumstances.

The average duration of vasomotor symptoms—7 to 11 years—represents a significant portion of a woman's life. Every woman deserves to navigate this transition with the best available evidence guiding her care.

---

## Sources

[^1]: HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy (2025). [https://www.hhs.gov/press-room/hhs-advances-womens-health-removes-misleading-fda-warnings-hormone-replacement-therapy.html](https://www.hhs.gov/press-room/hhs-advances-womens-health-removes-misleading-fda-warnings-hormone-replacement-therapy.html)

[^2]: The 2020 Menopausal Hormone Therapy Guidelines. PMC. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7475284/](https://pmc.ncbi.nlm.nih.gov/articles/PMC7475284/)

[^3]: Genitourinary Syndrome of Menopause: A Narrative Review. PMC. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10692865/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10692865/)

[^4]: 'Tis but a scratch: a critical review of WHI breast cancer evidence. PMC. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10758198/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10758198/)

[^5]: A comprehensive review of the safety and efficacy of bioidentical hormones. PubMed. [https://pubmed.ncbi.nlm.nih.gov/17217322/](https://pubmed.ncbi.nlm.nih.gov/17217322/)

[^6]: Compounded Bioidentical Menopausal Hormone Therapy. ACOG. [https://www.acog.org/clinical/clinical-guidance/clinical-consensus/articles/2023/11/compounded-bioidentical-menopausal-hormone-therapy](https://www.acog.org/clinical/clinical-guidance/clinical-consensus/articles/2023/11/compounded-bioidentical-menopausal-hormone-therapy)

[^7]: The Women's Health Initiative Hormone Therapy Trials: Update and Overview. PMC. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3963523/](https://pmc.ncbi.nlm.nih.gov/articles/PMC3963523/)

[^8]: 'Tis but a scratch: Statistical analysis of WHI findings. PMC. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10758198/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10758198/)

[^9]: Menopausal Hormone Replacement Therapy and Reduction of All-Cause Mortality and CVD. PMC. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9178928/](https://pmc.ncbi.nlm.nih.gov/articles/PMC9178928/)

[^10]: ELITE Trial: Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. NEJM. [https://www.nejm.org/doi/full/10.1056/NEJMoa1505241](https://www.nejm.org/doi/full/10.1056/NEJMoa1505241)

[^11]: When Women Initiate Estrogen Therapy Matters. The Menopause Society. [https://menopause.org/press-releases/when-women-initiate-estrogen-therapy-matters](https://menopause.org/press-releases/when-women-initiate-estrogen-therapy-matters)

[^12]: Estrogen and Cardiovascular Disease: Is Timing Everything? PMC. [https://pmc.ncbi.nlm.nih.gov/articles/PMC4490077/](https://pmc.ncbi.nlm.nih.gov/articles/PMC4490077/)

[^13]: Vasomotor Symptoms During Menopause: A Practical Guide. PMC. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9938702/](https://pmc.ncbi.nlm.nih.gov/articles/PMC9938702/)

[^14]: Role of menopausal hormone therapy in the prevention of postmenopausal osteoporosis. PMC. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10752002/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10752002/)

[^15]: Menopausal hormone therapy for the management of osteoporosis. PubMed. [https://pubmed.ncbi.nlm.nih.gov/34119418/](https://pubmed.ncbi.nlm.nih.gov/34119418/)

[^16]: The Role of Estrogen Therapy as a Protective Factor for Alzheimer's Disease. PMC. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10480684/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10480684/)

[^17]: Systematic review and meta-analysis of the effects of menopause hormone therapy on cognition. Frontiers. [https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1350318/full](https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1350318/full)

[^18]: Hormone replacement therapy is associated with improved cognition in at-risk APOE4 women. Alzheimer's Research & Therapy. [https://alzres.biomedcentral.com/articles/10.1186/s13195-022-01121-5](https://alzres.biomedcentral.com/articles/10.1186/s13195-022-01121-5)

[^19]: Effectiveness and safety of hormone replacement therapy in the treatment of menopausal syndrome: a meta-analysis. PMC. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11826161/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11826161/)

[^20]: Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. PMC. [https://pmc.ncbi.nlm.nih.gov/articles/PMC1974841/](https://pmc.ncbi.nlm.nih.gov/articles/PMC1974841/)

[^21]: The benefits and risks of menopause hormone therapy for the cardiovascular system: systematic review and meta-analysis. PMC. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10804786/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10804786/)

[^22]: Hormonal therapies and venous thrombosis: Considerations for prevention and management. PMC. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9399360/](https://pmc.ncbi.nlm.nih.gov/articles/PMC9399360/)

[^23]: Risk of stroke in healthy postmenopausal women during and after hormone therapy. PubMed. [https://pubmed.ncbi.nlm.nih.gov/24686450/](https://pubmed.ncbi.nlm.nih.gov/24686450/)

[^24]: Risk of Stroke With Various Types of Menopausal Hormone Therapies. Stroke/AHA. [https://www.ahajournals.org/doi/10.1161/strokeaha.117.017132](https://www.ahajournals.org/doi/10.1161/strokeaha.117.017132)

[^25]: Hormone Replacement Therapy - StatPearls. NCBI. [https://www.ncbi.nlm.nih.gov/books/NBK493191/](https://www.ncbi.nlm.nih.gov/books/NBK493191/)

[^26]: Effects of transdermal versus oral hormone replacement therapy in postmenopause: a systematic review. PMC. [https://pmc.ncbi.nlm.nih.gov/articles/PMC10147786/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10147786/)

[^27]: Genitourinary Syndrome of Menopause: AUA/SUFU/AUGS Guideline (2025). AUA. [https://www.auanet.org/guidelines-and-quality/guidelines/genitourinary-syndrome-of-menopause](https://www.auanet.org/guidelines-and-quality/guidelines/genitourinary-syndrome-of-menopause)

[^28]: When to take hormone replacement therapy (HRT). NHS. [https://www.nhs.uk/medicines/hormone-replacement-therapy-hrt/when-to-take-hormone-replacement-therapy-hrt/](https://www.nhs.uk/medicines/hormone-replacement-therapy-hrt/when-to-take-hormone-replacement-therapy-hrt/)

[^29]: Starting or continuing HRT many years after your menopause. The Menopause Charity. [https://themenopausecharity.org/information-and-support/what-can-help/treatment-options/starting-or-continuing-hrt-many-years-after-your-menopause/](https://themenopausecharity.org/information-and-support/what-can-help/treatment-options/starting-or-continuing-hrt-many-years-after-your-menopause/)

[^30]: How Long Should I Take Hormone Therapy in Menopause? Evernow. [https://www.evernow.com/learn/how-long-should-i-take-hormone-replacement-therapy](https://www.evernow.com/learn/how-long-should-i-take-hormone-replacement-therapy)

[^31]: Ongoing Individualized Hormone Therapy Appears to Have No Age Limit. The Menopause Society. [https://menopause.org/press-releases/ongoing-individualized-hormone-therapy-appears-to-have-no-age-limit](https://menopause.org/press-releases/ongoing-individualized-hormone-therapy-appears-to-have-no-age-limit)

[^32]: Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long? Circulation. [https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.061559](https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.061559)

[^33]: Menopausal Hormone Therapy and Heart Risk: Updated Guidance. Cleveland Clinic. [https://consultqd.clevelandclinic.org/menopausal-hormone-therapy-and-heart-risk-updated-guidance-is-at-hand](https://consultqd.clevelandclinic.org/menopausal-hormone-therapy-and-heart-risk-updated-guidance-is-at-hand)
